October 2018 Review
ICER developed a report on anti-androgen drugs for high risk prostate cancer, including the following therapies: enzalutamide (Xtandi®, Astellas and Medivation), abiraterone acetate (Zytiga®, Janssen), apalutamide (Erleada™, Janssen).
- September 2009: Active surveillance and Radical prostatectomy
- December 2008: Brachytherapy and Proton beam therapy
Proton beam therapy was also the subject of an evidence review by ICER for the Washington State Health Care Authority in May 2014.
- November 2007: Intensity modulated radiation therapy (IMRT)
For questions or additional information, please contact firstname.lastname@example.org
ASSOCIATED MEETING & MATERIALS
Chicago Marriott at Medical District/UIC
625 S Ashland Ave
Chicago, IL 60607
The Midwest CEPAC deliberated and voted on evidence presented in ICER's report on anti-androgen drugs for high risk prostate cancer. During this meeting, the Council also discussed ICER's review of treatments for amyloidosis.
Open to public comment until April 2, 2018. Click here for more information on submitting a public comment, please visit our stakeholder engagement page.
Open to public comment until August 9, 2018. Click here for more information on submitting a public comment, please visit our stakeholder engagement page.